Men's Health · April 15, 2026 · 10 min read

Finasteride vs Dutasteride: Which Works Better for Hair Loss?

Last updated: October 16, 2026

Clinically reviewed by Bidwell Cranage, APRN, FNP-C & Ashley Cranage, APRN, FNP-C · April 15, 2026

Finasteride and dutasteride reduce DHT and can help male pattern hair loss, but they are not interchangeable. Finasteride 1 mg is FDA-approved for this use; dutasteride is off-label in the U.S. Dutasteride performed better on hair outcomes in a 24-week trial, while staying in the body much longer. This comparison explains what that evidence does, and does not, tell you.

How Both Drugs Work

Androgenetic alopecia is driven by dihydrotestosterone (DHT), a potent androgen created when the enzyme 5-alpha reductase converts testosterone. In genetically susceptible hair follicles on the scalp, DHT binds to androgen receptors and gradually miniaturizes the follicle — each growth cycle produces a thinner, shorter hair until the follicle essentially shuts down. Block DHT at the scalp level, and that miniaturization slows. Block it more aggressively, and in many men it partially reverses.

There are two isoforms of 5-alpha reductase that matter here:

Type I is expressed mainly in sebaceous glands, skin, and liver.
Type II is the dominant isoform in hair follicles, prostate, and genital skin.

Finasteride selectively inhibits type II 5-alpha reductase; dutasteride inhibits types I and II. That explains part of their pharmacology, but does not by itself determine the best treatment or predict an individual's side effects.

DHT Suppression: The Pharmacology in Plain Numbers

Serum DHT is the most commonly cited lab marker in the literature, and the numbers are fairly consistent across studies:

Finasteride 1 mg daily suppresses serum DHT by approximately 65–70%.
Dutasteride 0.5 mg daily suppresses serum DHT by approximately 90%.

On paper, that's a meaningful gap. Whether it translates to meaningfully better hair outcomes is the interesting question, and the answer is: somewhat, but less dramatically than the DHT numbers alone would suggest. Hair follicles have their own local concentrations of both enzyme isoforms, and scalp DHT does not map linearly to serum DHT. Still, in head-to-head studies, dutasteride tends to produce modestly higher hair counts.

The Evidence

Separate a measured trial outcome from a long-term treatment recommendation:

A direct comparison at relevant doses (2014)

Gubelin Harcha and colleagues randomized 917 men across dutasteride doses, finasteride 1 mg and placebo for 24 weeks. Dutasteride 0.5 mg improved hair count, hair width and frontal photographic ratings more than finasteride 1 mg. Read the randomized trial.

What the trial cannot establish

Overall adverse-event numbers and severity were similar between groups over 24 weeks. That is not proof of equivalent long-term safety or that a man with finasteride side effects will tolerate dutasteride. The trial also cannot tell you whether your own previous treatment has had enough time or whether the diagnosis is correct.

What the U.S. labels add

Finasteride's label includes hair-loss efficacy follow-up and trial and postmarketing warnings. Dutasteride's label describes BPH, semen effects, PSA interpretation, pregnancy exposure and prolonged persistence. BPH safety populations differ from younger men seeking hair-loss treatment.

A larger hair count at a fixed study visit is useful evidence, not a guarantee that switching drugs will be worthwhile for a particular person.

Side-by-Side Comparison

Feature	Finasteride	Dutasteride
Brand names	Propecia, Proscar	Avodart
Mechanism	Blocks Type II 5-AR	Blocks Type I and II 5-AR
Hair loss dose	1 mg daily	0.5 mg daily (off-label)
Serum DHT suppression	~65–70%	~90%
Half-life	6–8 hours	4–5 weeks
FDA status (hair loss)	Approved	Off-label
FDA-approved indication	1 mg: male pattern hair loss; 5 mg: BPH	BPH, not hair loss
Decades on market	Since 1997 (hair)	Since 2001 (BPH)
Pharmacy cost	Depends on quantity and pharmacy	Depends on quantity and pharmacy
Typical use in practice	First-line	Non-response or aggressive loss

Side Effects: Shared Concerns, Different Exposure

Both drugs can cause sexual and breast symptoms. Their labels and study populations should be considered separately rather than assigning one percentage to the whole class:

Decreased libido; report a change rather than assuming it must be tolerated
Erectile or ejaculation symptoms, including reports that continue after treatment
Ejaculatory volume reduction or decreased semen
Breast pain, enlargement, lumps or nipple discharge, which need assessment
Mood symptoms: finasteride labeling includes depression and suicidal thoughts or behavior; report changes on either drug
Lower PSA: tell the clinician interpreting the test which drug and dose you use. Dutasteride averages roughly a 50% fall within three to six months in BPH studies. Finasteride 1 mg also lowered median PSA by 40% to 50% after 48 weeks in men aged 40 to 60. The testing clinician should account for treatment and evaluate a confirmed rise from the lowest PSA. Finasteride trial.

In first-year finasteride 1 mg trials, combined sexual symptoms occurred in 3.8% versus 2.1% with placebo. Those rates do not measure persistent symptoms or establish dutasteride's risk. A longer drug half-life is one consideration if tolerability is uncertain; neither medicine is guaranteed to be the safer choice.

Persistent sexual symptoms after finasteride discontinuation are included in U.S. labeling, with frequency and mechanisms uncertain. EMA's 2025 review identified suicidal thoughts as a side effect of finasteride tablets, but did not establish a causal link with dutasteride. Stop finasteride 1 mg and seek medical advice for mood changes; get emergency help if you may act on suicidal thoughts or cannot stay safe. New breast symptoms also deserve prompt assessment.

The Half-Life Difference Matters More Than People Think

Finasteride has a plasma half-life of several hours; dutasteride's is about five weeks at steady state. Dutasteride can remain detectable for four to six months after stopping. Blood clearance, reversal of DHT suppression and recovery from a side effect are different things.

If you develop a side effect on dutasteride and stop, DHT suppression does not end quickly. Symptoms may persist for weeks to months.
Pregnancy exposure and fertility: people who are or could be pregnant should avoid broken or crushed finasteride tablets and should not handle dutasteride capsules, especially leaking ones. Discuss fertility plans separately; a blood-donation interval is not a conception rule.
Blood donation: the American Red Cross requires one month after the last finasteride dose and six months after dutasteride. Do not donate during treatment.

A shorter half-life may matter to a patient who values shorter exposure. It does not mean finasteride effects can always be undone quickly, particularly when persistent symptoms have been reported.

Sexual adverse effects may persist after dutasteride is stopped; the label says dutasteride’s role in that persistence is unknown. Report ongoing symptoms rather than assuming they will resolve when the medicine clears. Dutasteride label.

Who Should Start With Which?

Questions to discuss before finasteride:

You've never taken a 5-alpha reductase inhibitor
Your hair loss is mild to moderate (Norwood 2–4)
Whether a shorter drug exposure matters to you, without assuming rapid symptom recovery
You want a medication that's FDA-approved for your specific use
Your actual pharmacy quote for the prescribed quantity
Fertility plans, sexual symptoms, mood history, liver issues and PSA testing

Questions to discuss before dutasteride:

You've taken finasteride consistently for 12+ months with inadequate response
Whether the pattern, prior response and expected benefit justify off-label treatment
Any urinary or prostate symptoms, which need their own evaluation; Bidwell's hair-loss intake does not treat BPH
You've accepted that it's an off-label use in the U.S. and are comfortable with longer drug exposure

These are discussion points, not an automatic escalation algorithm. Bidwell offers clinician-reviewed oral options for adult men in its supported states. The clinician can recommend further evaluation instead of a prescription if the pattern or safety history does not fit.

Switching and Combining

Ask the prescriber whether a change is appropriate and exactly when to stop one medication and start another. Do not take finasteride and dutasteride together or create a washout schedule yourself. Review diagnosis, adherence, duration, side effects and fertility plans first; an unclear or changing pattern may need dermatology assessment.

Minoxidil uses a different mechanism and may be considered with one DHT blocker. The route matters: oral minoxidil has systemic and boxed heart risks; topical minoxidil has scalp and systemic precautions. Do not assume all combinations have the same trial evidence or add oral and topical minoxidil together without medical advice.

For the financial comparison, see finasteride and dutasteride treatment costs, including separate generic prescriptions, combination budgets and refill visit fees. A lower price does not determine which medicine is right for you.

Sources and evidence

These sources support the medication facts and research discussed above. Study results apply to the doses and populations tested; they do not guarantee an individual outcome.